ABBVQ3 20261/5Estimate vs Actual
Earnings per Share
$3.82
+ 1.3% vs Estimate
Surprise as recorded in the analysis; the estimate itself is not on the calendar.
AbbVie Inc Q3 2026 · Story
Read the quarter card by card, ready to share.
ABBVQ3 20261/5ABBVQ3 20262/5Guidance
Full-Year Adjusted EPS
- Company Guidance
- 13.95 – 13.99 $
- Market Estimate
- 13.95 $
In Line ✓
Full-Year Revenue
- Company Guidance
- 67.8 billion
- Market Estimate
- 67.58 billion
In Line ✓
Q4 Adjusted EPS
- Company Guidance
- 3.83 – 3.87 $
Flat
ABBVQ3 20263/5Price Reaction
First Full Session
+ 1.9%
From the prior close to the report-day close.
Post-Report Moves
- This Report+ 1.9%
- Jul 31− 2.5%
ABBVQ3 20264/5In 30 Seconds
Revenue of $17.40B and adjusted EPS of $3.82 landed in line with estimates.
- Skyrizi and Rinvoq grew 23% year over year; full-year guidance was raised to $13.95-13.99.
- The stock rose 1.9% intraday to a record, above the average analyst target.
First point of the analysis's “In 30 Seconds”.
Full AnalysisABBVQ3 20265/5Score
63/ 100
ViewHOLD
Not Investment Advice